secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2025-06-04T23:59:59+00:00
Accession:  0001867096-25-000104
Event type: other
Sentiment:  neutral
Materiality: 0.05
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Xeris Biopharma reports Annual Meeting voting results; all proposals approved
-----------------------------------------------------------------------------

- Three Class I directors elected: Bormann (57.1M for), Brady (76.5M for), Kong (75.9M for).
- Ratification of Ernst & Young as auditor for FY2025: 110.1M for, 0.7M against.
- Advisory say-on-pay compensation vote passed: 72.2M for, 5.6M against, 0.9M abstain.
- All proposals passed with required votes; no material changes to board or auditor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709625000104/0001867096-25-000104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709625000104/xers-20250604.htm
  HTML page:      https://secwatch.observer/filing/0001867096-25-000104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer